PGP and triple-negative breast carcinoma: Compound 15 showed strong inhibitionof viability in a panel of cancer cells, including colorectal cancerand triple-negative breast cancer cells, was effective against theNCI/ADR-RES DOX-resistant cell line, and restored the sensitivityto doxorubicin (DOX) in HT29/DX and MDCK/P-gp cells.